![[Updated] U.S. Air Force Mobilizes F-22s and F-35s as Situation in Middle East Escalates](https://theaviationist.com/wp-content/uploads/2025/06/F-22_F-35_CENTCOM-top.jpg)
![[Updated] Sudden Deployment of Dozens of U.S. Air Force Tankers Raises Questions](https://theaviationist.com/wp-content/uploads/2025/03/Stratotanker100Years_2-e1750080240327.jpg)
STAT+: Isomorphic Labs sets up U.S. presence, with an eye on clinical trials
As Isomorphic Labs aims its artificial intelligence tools at drug development, it’s setting up a new outpost in the biotech hub of Cambridge.
As Isomorphic Labs aims its artificial intelligence tools at drug development, it’s setting up a new outpost in the biotech hub of Cambridge.
Founded in 2021 as a spinoff of Alphabet AI company DeepMind, Isomorphic built off the protein structure-predicting power of the deep learning model AlphaFold. “Our core thesis was, and is, that we can use AI to really transform and reimagine how we discover drugs,” said Isomorphic President Colin Murdoch.
After developing AlphaFold into a drug design platform, the company has entered the era where it is progressing some of those AI-enabled drug candidates toward clinical trials — and to do that, it needs a footprint in the United States.
